Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 231-236

  Gao, Ying ^a,b   Li, Yunfeng ^a   Xue, Jing ^a   Jia, Yongqian ^c   Hu, Jing ^a  

^a SICHUAN UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Bone density; Bone quality; Metformin; Osteoblast markers; Ovariectomy

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; METFORMIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE MASS; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE EXPRESSION; HISTOLOGY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA;

ABSORPTIOMETRY, PHOTON; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; FEMALE; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; METFORMIN; OSTEOBLASTS; OSTEOPETROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 77952321206     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.051     Document Type: Article

References (26)

1. Allen K.V., Frier B.M., Strachan M.W.J. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur. J. Pharmacol. 2004, 490:169-175.
2. Blagosklonny M.V. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov. Today 2007, 12:218-224.
3. Carnevale V., Romagnoli E., D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diab. Metab. Res. Rev. 2004, 20:196-204.
4. Chau D.L., Edelman S.V., Chandran M. Osteoporosis and diabetes. Curr. Diab. Rep. 2003, 3:37-42.
5. Cortizo A.M., Sedlinsky C., McCarthy A.D., Blanco A., Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblast in culture. Eur. J. Pharmacol. 2006, 536:38-46.
6. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 2005, 8:739-750.
7. Ducy P., Zhang R., Geoffroy V., Ridall A., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
8. 3 inhibit bone marrow adipogenesis in senescence acclerated mice(SAM-P/6) by decreasing the expression of peroxisome proliferators-activated receptor gamma2 (PPARγ2). Exp. Gerontol. 2004, 39:333-338.
9. Gaur T., Lengner C.J., Hovhannisyan H. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J. Biol. Chem. 2005, 280:33,132-33,140.
10. Giugliano D., Rosa N.D., Maro G.N., Marfella R., Acampora R., Buoninconti R., D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive obese women. Diab. Care 1993, 16:1387-1390.
11. Hanson N.A., Cedo M.B. Alternative approach to assessment of bone quality using micro-computed tomography. Bone 2004, 35:326-333.
12. Hill T.P., Spater D., Taketo M.M. Canonical Wnt/betacatenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 2005, 8:727-738.
13. Itoh F., Aoyagi S., Furihata-Komatsu H., Aoki M., Kusama H., Kojima M., Kogo H. Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur. J. Pharmacol. 2003, 477:9-16.
14. Kanazawa I., Yamaguchi T., Yano S. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem. Biophy. Res. Commun. 2008, 375:414-419.
15. Katayama Y., Akatsu T., Yamamoto M., Kugai N., Nagata N. Role of non-enzymatic glycosylation of type I collagen in diabetic osteopenia. J. Bone Miner. Res. 1996, 11:931-937.
16. Kneissel M. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 2004, 35:1144-1156.
17. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
18. Lecka-Czernik B., Gubrij I., Moerman E.J., Kajkenova O., Lipschitz D.A., Manolagas S.C. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J. Cell. Biochem. 1999, 74:357-371.
19. Levasseur R., Lacombe D., de Vernejoul M.C. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 2005, 72:207-214.
20. Manolagas S.C., Kousteni S., Jilka R.L. Sex steroids and bone. Recent Prog. Horm. Res. 2002, 57:385-409.
21. McCarthy A.D., Etcheverry S.B., Bruzzone L., Cortizo A.M. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol. Cell. Biochem. 1997, 170:43-51.
22. Paolisso G. Low insulin resistance and preserved b-cell function contribute to human longevity but are not associated with TH-INS genes. Exp. Gerontol. 2001, 37:149-156.
23. Tang Z.H., Sahu S.N., Khadeer M.A., Bai G., Franklin R.B., Gupta A. Overexpression of the ZIP1 zinc transporter induces an osteogenic phenotype in mesenchymal stem cells. Bone 2006, 38:181-198.
24. Van H.D. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 2005, 4:79-85.
25. Vestergaard P., Rejnmark L., Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005, 48:1292-1299.
26. Wang F.S., Lin C.L., Chen Y.J. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 2005, 146:2415-2423.